Catherine Daly

<i>KRAS</i> and <i>BRAF</i> Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial

Susan D. Richman, Philip Chambers, Faye Elliott et al. · Journal of Clinical Oncology · 2009 · 569 citations

Medicine, Molecular Genetics, Oncology +17

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

Michael Braun, Susan D. Richman, Philip Quirke et al. · Journal of Clinical Oncology · 2008 · 275 citations · Full text

Medicine, Oncology, Pharmacology +17

Association of Molecular Markers With Toxicity Outcomes in a Randomized Trial of Chemotherapy for Advanced Colorectal Cancer: The FOCUS Trial

Michael Braun, Susan D. Richman, Lindsay C Thompson et al. · Journal of Clinical Oncology · 2009 · 128 citations

Medicine, Oncology, Pharmacology +17

Using next-generation sequencing for high resolution multiplex analysis of copy number variation from nanogram quantities of DNA from formalin-fixed paraffin-embedded specimens

Henry M. Wood, Ornella Belvedere, Caroline Conway et al. · Nucleic Acids Research · 2010 · 111 citations · Full text

Life Sciences, Molecular Biology, Pathology +17

Intra-tumoral heterogeneity of KRAS and BRAF mutation status in patients with advanced colorectal cancer (aCRC) and cost-effectiveness of multiple sample testing.

Susan D. Richman, Philip Chambers, Catherine Daly et al. · PubMed · 2011 · 78 citations

Medicine, Genetics, Oncology +17